{"id":63026,"date":"2026-04-13T20:34:44","date_gmt":"2026-04-13T12:34:44","guid":{"rendered":"https:\/\/flcube.com\/?p=63026"},"modified":"2026-04-13T20:34:45","modified_gmt":"2026-04-13T12:34:45","slug":"iaso-biotherapeutics-partners-with-brazils-butantan-institute-to-localize-car-t-therapy-for-hematological-cancers","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63026","title":{"rendered":"IASO Biotherapeutics Partners with Brazil&#8217;s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers"},"content":{"rendered":"\n<p><strong>IASO Biotherapeutics<\/strong>, a Chinese cell therapy innovator, has entered into a strategic <strong>technology collaboration and licensing agreement<\/strong> with Brazil\u2019s <strong>Butantan Institute<\/strong>, the largest producer of vaccines and sera in Latin America. The partnership aims to establish a localized <strong>CAR-T cell therapy<\/strong> development and manufacturing capability in Brazil to treat <strong>hematological malignancies<\/strong>, leveraging the patient\u2019s own immune cells as a living drug.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-framework-amp-infrastructure\">Partnership Framework &amp; Infrastructure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>IASO Biotherapeutics (China) &amp; Butantan Institute (Brazil)<\/td><\/tr><tr><td><strong>Focus<\/strong><\/td><td>Local development and manufacturing of CAR-T therapies for blood cancers<\/td><\/tr><tr><td><strong>Manufacturing Site<\/strong><\/td><td>S\u00e3o Paulo Advanced Therapy Center (Nutera-SP)<\/td><\/tr><tr><td><strong>Facility Operator<\/strong><\/td><td>Butantan Institute<\/td><\/tr><tr><td><strong>Infrastructure<\/strong><\/td><td>Specialized GMP facility equipped for advanced cell therapy production<\/td><\/tr><tr><td><strong>Butantan&#8217;s Role<\/strong><\/td><td>Latin America\u2019s leading public immunobiologics manufacturer<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Access &amp; Localization:<\/strong> The deal provides IASO with a direct pathway to the large and underserved Brazilian and broader Latin American markets by establishing a local manufacturing footprint, which is critical for the complex logistics of autologous cell therapies.<\/li>\n\n\n\n<li><strong>Leveraging Public Health Expertise:<\/strong> Partnering with the <strong>Butantan Institute<\/strong>, a cornerstone of Brazil\u2019s public health system, offers IASO access to unparalleled regulatory experience, clinical networks, and a mission-aligned partner focused on broad patient access.<\/li>\n\n\n\n<li><strong>Building Regional Capacity:<\/strong> The use of the state-of-the-art <strong>Nutera-SP<\/strong> facility will help build Latin America\u2019s domestic capacity for advanced therapy medicinal products (ATMPs), reducing reliance on expensive imports and improving treatment accessibility.<\/li>\n\n\n\n<li><strong>Technology Transfer:<\/strong> IASO will license its proprietary CAR-T platform technology to Butantan, enabling the local production of these sophisticated therapies under its technical guidance.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-implications\">Market Context &amp; Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressing Unmet Need:<\/strong> Hematological malignancies like leukemia and lymphoma represent a significant health burden in Brazil. Localized CAR-T production could dramatically improve patient outcomes by making this cutting-edge therapy more accessible and affordable.<\/li>\n\n\n\n<li><strong>Emerging Markets Strategy:<\/strong> This collaboration exemplifies a new model for Chinese biotech firms, moving beyond simple product export to deep, infrastructure-based partnerships that build sustainable healthcare ecosystems in emerging markets.<\/li>\n\n\n\n<li><strong>Public-Private Innovation:<\/strong> The alliance between a private Chinese biotech and a major public Brazilian institution highlights a powerful synergy for accelerating the adoption of advanced therapies in resource-conscious settings.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief describes a strategic collaboration. The successful development, regulatory approval, and commercialization of CAR-T therapies in Brazil are subject to numerous scientific, regulatory, and operational challenges. There can be no assurance of success or market launch.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>IASO Biotherapeutics, a Chinese cell therapy innovator, has entered into a strategic technology collaboration and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[77],"class_list":["post-63026","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cell-therapy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>IASO Biotherapeutics Partners with Brazil&#039;s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"IASO Biotherapeutics, a Chinese cell therapy innovator, has entered into a strategic technology collaboration and licensing agreement with Brazil\u2019s Butantan Institute, the largest producer of vaccines and sera in Latin America. The partnership aims to establish a localized CAR-T cell therapy development and manufacturing capability in Brazil to treat hematological malignancies, leveraging the patient\u2019s own immune cells as a living drug.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63026\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IASO Biotherapeutics Partners with Brazil&#039;s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers\" \/>\n<meta property=\"og:description\" content=\"IASO Biotherapeutics, a Chinese cell therapy innovator, has entered into a strategic technology collaboration and licensing agreement with Brazil\u2019s Butantan Institute, the largest producer of vaccines and sera in Latin America. The partnership aims to establish a localized CAR-T cell therapy development and manufacturing capability in Brazil to treat hematological malignancies, leveraging the patient\u2019s own immune cells as a living drug.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63026\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-13T12:34:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-13T12:34:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63026#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63026\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"IASO Biotherapeutics Partners with Brazil&#8217;s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers\",\"datePublished\":\"2026-04-13T12:34:44+00:00\",\"dateModified\":\"2026-04-13T12:34:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63026\"},\"wordCount\":409,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cell-therapy\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63026#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63026\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63026\",\"name\":\"IASO Biotherapeutics Partners with Brazil's Butantan Institute to Localize CAR-T Therapy for Hematological Cancers - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-13T12:34:44+00:00\",\"dateModified\":\"2026-04-13T12:34:45+00:00\",\"description\":\"IASO Biotherapeutics, a Chinese cell therapy innovator, has entered into a strategic technology collaboration and licensing agreement with Brazil\u2019s Butantan Institute, the largest producer of vaccines and sera in Latin America. The partnership aims to establish a localized CAR-T cell therapy development and manufacturing capability in Brazil to treat hematological malignancies, leveraging the patient\u2019s own immune cells as a living drug.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63026#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63026\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63026#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IASO Biotherapeutics Partners with Brazil&#8217;s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"IASO Biotherapeutics Partners with Brazil's Butantan Institute to Localize CAR-T Therapy for Hematological Cancers - Insight, China&#039;s Pharmaceutical Industry","description":"IASO Biotherapeutics, a Chinese cell therapy innovator, has entered into a strategic technology collaboration and licensing agreement with Brazil\u2019s Butantan Institute, the largest producer of vaccines and sera in Latin America. The partnership aims to establish a localized CAR-T cell therapy development and manufacturing capability in Brazil to treat hematological malignancies, leveraging the patient\u2019s own immune cells as a living drug.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63026","og_locale":"en_US","og_type":"article","og_title":"IASO Biotherapeutics Partners with Brazil's Butantan Institute to Localize CAR-T Therapy for Hematological Cancers","og_description":"IASO Biotherapeutics, a Chinese cell therapy innovator, has entered into a strategic technology collaboration and licensing agreement with Brazil\u2019s Butantan Institute, the largest producer of vaccines and sera in Latin America. The partnership aims to establish a localized CAR-T cell therapy development and manufacturing capability in Brazil to treat hematological malignancies, leveraging the patient\u2019s own immune cells as a living drug.","og_url":"https:\/\/flcube.com\/?p=63026","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-13T12:34:44+00:00","article_modified_time":"2026-04-13T12:34:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63026#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63026"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"IASO Biotherapeutics Partners with Brazil&#8217;s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers","datePublished":"2026-04-13T12:34:44+00:00","dateModified":"2026-04-13T12:34:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63026"},"wordCount":409,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cell-therapy"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63026#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63026","url":"https:\/\/flcube.com\/?p=63026","name":"IASO Biotherapeutics Partners with Brazil's Butantan Institute to Localize CAR-T Therapy for Hematological Cancers - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-13T12:34:44+00:00","dateModified":"2026-04-13T12:34:45+00:00","description":"IASO Biotherapeutics, a Chinese cell therapy innovator, has entered into a strategic technology collaboration and licensing agreement with Brazil\u2019s Butantan Institute, the largest producer of vaccines and sera in Latin America. The partnership aims to establish a localized CAR-T cell therapy development and manufacturing capability in Brazil to treat hematological malignancies, leveraging the patient\u2019s own immune cells as a living drug.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63026#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63026"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63026#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"IASO Biotherapeutics Partners with Brazil&#8217;s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63026","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63026"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63026\/revisions"}],"predecessor-version":[{"id":63028,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63026\/revisions\/63028"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63026"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63026"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63026"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}